From: Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
LNP name | mRNA | Cancer type | Pharmacological effects and feedback | Refs. |
---|---|---|---|---|
Cationic LNP | OVA and the control EGFP mRNA | Lymphoma | Significant increase in expression of CD80 and CD86 in the splenic CD11+ T-lymphocytes Increased CD69+ T-cells of the spleen and the lymph nodes was the other sign of activation of T-cell responses | [174] |
Ionizable lipid-based NPs (OF-Deg-Lin) | Human factor VIII (hFVIII) mRNA | Successful induction of protein expression and production in the B-cells of the spleen | [184] | |
LNP | IL-12A mRNA | Hepatocellular carcinoma | Enhancement of activated CD44+ immune cells such as CD3+ and CD4+ Th cells following IL-12 expression, shrinkage of tumor size, and increased survival in mice | [185] |
cKK-E12 LNP | in vitro-transcribed mRNA was designed and formulated by cKK-E12 LNP to produce trastuzumab, an anti-HER2 monoclonal antibody | Breast cancer | In vivo PK characteristics of trastuzumab mRNA vs. synthetic trastuzumab (Herceptin®) in C57BL/6 mice: the significant higher serum level of trastuzumab, and interestingly the used dosage of this system was lower than Herceptin®, the higher morbidity-free survival in HER2+ mice and the lower average tumor volume via trastuzumab mRNA | [180] |
PEG-coated hybrid of a cationic lipid-like compound (G0-C14) and poly lactic-co-glycolic acid (PLGA) | PTEN mRNA | Prostate cancer | Decrease in tumor size and weight with the least adverse effects on body weight increased apoptosis and declined survival of tumor cells | [36] |